ENERGI-F705 not checked
Energenesis Biomedical Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Parkinson's Disease (PD)
- Main trialPhase 2
- “The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is: Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment? Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no…”In the company’s words, NCT07647614 on ClinicalTrials.gov
Other drugs for Parkinson's Disease (PD)
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibEisai · Merck & Co. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up1
- 1 Jan 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Jan 2030 | A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease | |
| Phase 1Completed | 6 May 2025 | A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026